Form 8-K - Current report:
SEC Accession No. 0001104659-25-061165
Filing Date
2025-06-20
Accepted
2025-06-20 16:14:33
Documents
12
Period of Report
2025-06-18
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518556d1_8k.htm   iXBRL 8-K 31227
  Complete submission text file 0001104659-25-061165.txt   198878

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA avbp-20250618.xsd EX-101.SCH 3014
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE avbp-20250618_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avbp-20250618_pre.xml EX-101.PRE 22358
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2518556d1_8k_htm.xml XML 3815
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 251061510
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)